Prognostic Value of 2-Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography/Computed Tomography after Autologous Hematopoietic Stem Cell Transplantation in Lymphoma Using Deauville Scores

被引:4
作者
Dai, Na [1 ]
Zhou, Yeye [1 ]
Deng, Shengming [1 ]
Sang, Shibiao [1 ]
Wu, Yiwei [1 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Dept Nucl Med, Suzhou 215006, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
HODGKIN-LYMPHOMA; FDG-PET; RESPONSE ASSESSMENT; AGGRESSIVE LYMPHOMA; PREDICTIVE-VALUE; FREE SURVIVAL; CRITERIA; CHEMOTHERAPY; CONSENSUS; CONSOLIDATION;
D O I
10.1155/2021/5510825
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose. In the present study, we mainly aimed to evaluate the prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose ([F-18]F-FDG) positron emission tomography (PET)/computed tomography (CT) after autologous stem cell transplantation (ASCT) in lymphoma. Procedures. A total of 76 lymphoma patients who benefited from [F-18]F-FDG PET-CT (within 3 months and 3-6 months) after ASCT in our institution between April 2010 and December 2019 were enrolled in this retrospective study. These above mentioned patients were divided into two groups based on the Deauville criteria. The Kaplan-Meier method was used in survival analysis, and the log-rank method was adopted in comparison. Prognostic factor analysis was performed by the Cox regression model. Results. Positive post-ASCT [F-18]F-FDG PET-CT was associated with lower progression-free survival (PFS) and overall survival (OS) (p=0.001 and p=0.022, respectively). Univariate analysis showed the post-ASCT PET-CT result was the only independent factor associated with PFS (p=0.002). Both the number of previous treatments and post-ASCT PET-CTresult had a different impact on OS (p=0.040 and p=0.028, respectively). Multivariate analysis showed the post-ASCT PET-CTresult was the only independent factor associated with OS (p=0.028). The results showed no significant change from the above mentioned results when DS < 3 was defined as the negative result. For patients who had a PET-CT scan within 3-6 months after ASCT, the negative PET-CT group had a better prognosis including PFS and OS (p=0.009 and p=0.025, respectively). However, among the patients receiving PET-CT within 3 months, the result was not statistically significant (p=0.064 and p=0.445, respectively). Conclusion. Collectively, we found that the post-ASCT [F-18]F-FDG PET-CT was a strong indicator for PFS and OS, and a time window of 3-6 months was appropriate for post-ASCT [F-18] F-FDG PET-CT.
引用
收藏
页数:8
相关论文
共 42 条
[1]   Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis [J].
Adams, Hugo J. A. ;
Kwee, Thomas C. .
ANNALS OF HEMATOLOGY, 2016, 95 (05) :695-706
[2]   Pre-transplant 18F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT [J].
Akhtar, S. ;
Al-Sugair, A. S. ;
Abouzied, M. ;
AlKadhi, Y. ;
Dingle, M. ;
Abdelsalam, M. ;
Soudy, H. ;
Darwish, A. ;
Eltigani, A. ;
Elhassan, T. A. M. ;
Nabil-Ahmed, M. ;
Maghfoor, I. .
BONE MARROW TRANSPLANTATION, 2013, 48 (04) :551-556
[3]   PET/CT before autologous stem cell transplantation predicts [J].
Alcantara, Marion ;
Dupuis, Jehan ;
Mareschal, Sylvain ;
Julian, Anne ;
Cottereau, Anne Segolene ;
Becker, Stephanie ;
Dubois, Sydney ;
Oberic, Lucie ;
Huynh, Anne ;
Meignan, Michel ;
Laurent, Guy ;
Tilly, Herve ;
Haioun, Corinne ;
Ysebaert, Loic .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) :215-221
[4]   Non-Hodgkin lymphoma [J].
Armitage, James O. ;
Gascoyne, Randy D. ;
Lunning, Matthew A. ;
Cavalli, Franco .
LANCET, 2017, 390 (10091) :298-310
[5]   Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group [J].
Barrington, Sally F. ;
Mikhaeel, N. George ;
Kostakoglu, Lale ;
Meignan, Michel ;
Hutchings, Martin ;
Mueeller, Stefan P. ;
Schwartz, Lawrence H. ;
Zucca, Emanuele ;
Fisher, Richard I. ;
Trotman, Judith ;
Hoekstra, Otto S. ;
Hicks, Rodney J. ;
O'Doherty, Michael J. ;
Hustinx, Roland ;
Biggi, Alberto ;
Cheson, Bruce D. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3048-+
[6]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[7]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[8]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[9]   Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].
Cheson, Bruce D. ;
Fisher, Richard I. ;
Barrington, Sally F. ;
Cavalli, Franco ;
Schwartz, Lawrence H. ;
Zucca, Emanuele ;
Lister, T. Andrew .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+
[10]   Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation [J].
Filmont, JE ;
Czernin, J ;
Yap, C ;
Silverman, DHS ;
Quon, A ;
Phelps, ME ;
Emmanouilides, C .
CHEST, 2003, 124 (02) :608-613